Companies /Healthcare

Agios Pharmaceuticals Inc

NASDAQ: AGIO Biotechnology
$31.93
▲ $0.01 (+0.02%) today
Markets open · 10:37am ET

AGIO at a Glance

Valuation
Market cap
$1.9B
Profitability
Revenue (TTM)
$98.3M
EPS (TTM)
$-7.01
Price
52-week range
$22 – $46
Street target
$46.00
Earnings
Next report
Oct 29, 2026

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: AGIO agios.com

About Agios Pharmaceuticals

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering innovative medicines for patients with rare diseases, with a core foundation in hematology. The company's commercial portfolio centers on mitapivat, a pyruvate kinase (PK) activator marketed as PYRUKYND and AQVESME, approved for the treatment of anemia associated with thalassemia in the U.S., EU, Saudi Arabia, and the United Arab Emirates. Agios is pursuing regulatory approval of mitapivat in sickle cell disease under the FDA's accelerated approval pathway. The company's pipeline includes AG-236, an siRNA targeting TMPRSS6 in development for polycythemia vera; AG-181, a phenylalanine hydroxylase stabilizer for phenylketonuria; and cevidoplenib, a next-generation oral SYK inhibitor licensed from Oscotec for immune thrombocytopenia. Agios trades on the Nasdaq under the ticker AGIO. Updated

Latest Activity

House trade disclosureGilbert Ray Cisneros, Jr.
  • AMDAdvanced Micro Devices, Inc. (AMD)Partial sell$1K – $15KAug 18
  • AGIO150 Main Street Trust > Bank of America Agios Pharmaceuticals, Inc. - Common StoBuy$1K – $15KAug 20
  • APH150 Main Street Trust > Bank of America Amphenol Corporation Common Stock (APH)Buy$1K – $15KAug 18
  • APG150 Main Street Trust > Bank of America APi Group Corporation Common Stock (APG)Buy$1K – $15KAug 4
  • APP150 Main Street Trust > Bank of America Applovin Corporation - Class A Common StPartial sell$1K – $15KAug 18
  • AORT150 Main Street Trust > Bank of America Artivion, Inc. Common Stock (AORT)Buy$1K – $15KAug 20
  • ATRCAtriCure, Inc. - Common Stock (ATRC)Buy$1K – $15KAug 20
  • BSX150 Main Street Trust > Bank of America Boston Scientific Corporation Common StoBuy$1K – $15KAug 18
+ 42 more trades in this filing
Made public 37 days after the earliest trade

Fifty-eight transactions in one filing amount to a full portfolio rebuild: bigger-ticket buys in Microsoft, Eaton, Quanta Services and Globus Medical, funded partly by repeated Lamar Advertising sales and trims in AMD, Nvidia and Meta. The rotation leans toward power, infrastructure and medical devices while chip and ad-tech exposure comes down. Disclosed 37 days after the earliest trades.

Read more

AGIO Coverage

9:54am ET
Health and Healthcare

Agios Pharma’s Big Bet on Anemia

Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.

AGIO
Chris Lange

Frequently Asked Questions

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering innovative medicines for patients with rare diseases, with a core foundation in hematology.

What is the AGIO stock price target?

The Wall Street consensus 12-month price target for AGIO is $46.00.